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Summary Both pressure- and volume-limited non-invasive positive pressure
ventilation (NPPV) have been used in patients with chronic respiratory failure. The
aim of the present study was to compare the efficacy of ventilation during nocturnal
volume- and pressure-limited NPPV.
Fifteen patients (nine COPD, six non-COPD) were randomly assigned to receive
either volume-limited or pressure-limited NPPV and were switched to the
complementary mode after 6 weeks.
Ten patients (five COPD, five non-COPD) completed the study. PaCO2 during sleep
comparably decreased from 54.678.0 to 46.276.1mmHg during volume-limited
NPPV (Po0.05), and to 46.576.4mmHg during pressure-limited NPPV (Po0.05).
Improvements in sleep quality assessed by polysomnography were comparable, but
less gastrointestinal side effects were reported for pressure-limited NPPV (Po0.05).
Using a pneumotachograph the variance of inspiratory volumes was lower, but the
variance of peak inspiratory pressures was higher during volume-limited NPPV
compared to pressure-limited NPPV. Substantial leak volumes which accounted for
57% (volume-limited NPPV) and for 58% (pressure-limited NPPV) of the applied
inspiratory volume were independent from the mode of ventilation.
In conclusion, nocturnal volume- and pressure-limited NPPV have similar effects
on gas exchange and sleep quality in patients with hypercapnic chronic respiratory
failure, but volume-limited NPPV is associated with more gastrointestinal side
effects.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Non-invasive positive pressure ventilation (NPPV) is
a well established and increasingly used therapeu-
tic option for patients with hypercapnic chronic
respiratory failure (CRF). Most patients with hy-
percapnic CRF suffer from advanced chronic ob-
structive pulmonary disease (COPD), chest wall
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deformities, or neuromuscular diseases. Here,
NPPV has been shown to improve several clinically
relevant parameters such as gas exchange, respira-
tory muscle function, and sleep quality.1,2
There are in principal two different modes of
how NPPV can be applied: volume-limited NPPV (vl-
NPPV) and pressure-limited NPPV (pl-NPPV).2,3
During vl-NPPV a predetermined tidal volume (VT)
or minute volume (MV) is delivered leading to
varying peak inspiratory pressures (Pinsp) depending
on the resistance of the respiratory system. In
contrast, a predetermined Pinsp is delivered
during pl-NPPV which can cause different VT
depending on the resistance of the respiratory
system. Pl-NPPV has been suggested to have the
advantage of leak compensation, since inspiratory
flow increases during leakage more or less suffi-
ciently depending on the ventilator used for pl-
NPPV.4 On the other hand, VT delivered by pl-NPPV
can decrease during increased resistance of the
respiratory system such as airway obstruction
which may lead to insufficient ventilation. Accord-
ingly, the Pinsp will be increased during vl-NPPV
when the resistance increases in order to maintain
the predetermined VT, but leak compensation
during vl-NPPV is less evident.4
In clinical practice, pl-NPPV is generally pre-
ferred to vl-NPPV in patients with home mechanical
ventilation as shown by a recent European
prevalence study including 19 000 patients from
16 different countries,5 and pl-NPPV has progres-
sively replaced vl-NPPV in patients with CRF in the
last years.6 However, clear advantages for either
pl-NPPV or vl-NPPV have not yet been demon-
strated in comparative studies where both
modes of NPPV were applied.7–10 Two of these
studies investigated long-term effects of pl- and
vl-NPPV.9,10 In the study by Sch .onhofer and co-
workers, vl-NPPV was considered to be superior to
pl-NPPV in only a small subgroup of patients with
severe CRF,9 but in the study by Smith and
Shneerson pl-NPPV was able to improve arterial
blood gases (ABG) in selected patients who failed
after a long-term interval of vl-NPPV.10 However,
both studies are limited by their uncontrolled
design and by the lack of concomitant sleep
studies, although NPPV is predominantly used
during the night in patients with CRF. Furthermore,
the delivery of VT and capabilities of leak compen-
sation have yet not been comparably studied in a
clinical setting at night. Therefore, the aim of the
present study was to investigate the ventilation
pattern of vl- and pl-NPPV at night in order to
compare the efficacy of ventilation with either
mode of nocturnal NPPV in a prospective, rando-
mized, cross-over trial.
Methods
The study protocol was approved by the institu-
tional review board for human studies and was
executed in accordance with the ethical standards
laid down in the Declaration of Helsinki. Informed
written consent was obtained from all participants.
Patients
Only patients with stable disease who were
hospitalized to initiate home mechanical ventila-
tion and who had clinical indicators as suggested by
international consensus criteria1 were enrolled.
Patients who had evidence of acute respiratory
failure (ARF), i.e. patients with worsening symp-
toms during the last 2 weeks, a breathing frequency
ðfBÞ430=min; a pHo7.35 or signs of respiratory
infections (two of the following: coloured sputum,
fever, infiltration on the chest X-ray, white blood
cell count (WBC)410 000/ml) were excluded from
the study. In addition, patients who had been
intubated during the last 3 months, or had invasive
ventilation following tracheostomy, or any other
form of ventilatory support prior to admission were
also excluded.
Study design
Patients were randomly assigned to receive either
nasal vl-NPPV (PLV-100s, Respironics Inc., Murrys-
ville, USA) or pl-NPPV (PV401s, Breas Medical AB,
Moelnlycke, Sweden) in the assist/control mode.
The nasal mask (Contour Nasal Mask, Respironics
Inc., Murrysville, USA) used as patient-ventilator
interface was not changed during the study period.
In addition, all participants used an one-way circuit
with an expiratory valve that was not changed
during the study, since differences between ex-
piratory valve resistance might be of clinical
importance.11 In addition, all patients received
passive humidification.
NPPV was initiated with the aim to achieve
passive ventilation with a maximal decrease of
PaCO2 as has been previously described.
12 This
allowed to compare the two modes of NPPV
excluding possible differences in triggering, since
different triggering and trigger techniques have
been shown to significantly influence the efficacy of
ventilation.13,14 Supplemental oxygen was added to
NPPV to reach a nocturnal oxygen saturation
(SaO2)490% during the night. Patients were ad-
mitted again for the first control visit after 6 weeks
of home mechanical ventilation and were subse-
quently switched to the other mode of ventilation.
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For ventilator settings of the second mode of
ventilation the fB was adopted from the first
ventilator. In addition Pinsp and Vinsp, respectively,
were again initiated with the aim of a maximal
decrease in PaCO2. After discharge and another 6
weeks of home mechanical ventilation using the
second ventilator patients were re-hospitalized for
the second control visit.
Measurements during daytime without NPPV
WBC, haemoglobin, haematocrit, and C-reactive
protein (CRP) recorded from a venous blood sample
as well as ABG at rest taken from the arterialized
earlobe (AVL OMNIs, Roche Diagnostics GmbH,
Graz, Austria), pulmonary function parameters
(Masterlab-Compacts Labor, Jaeger, Hochberg,
Germany), and inspiratory mouth occlusion pres-
sures (ZAN 100s, ZAN Geraetetechnik GmbH,
Oberthulba, Germany) were measured at baseline
and at both control visits after establishment of
NPPV. A chest X-ray was performed prior to NPPV. A
non-standardized questionnaire including eight
items regarding tolerance of NPPV with values of
þ 2 indicating maximal comfort and values of 2
indicating maximal discomfort was answered by
each patient during both control visits.
Measurements during night
Full polysomnography (SIDAS GSs, Heinen & Loe-
wenstein, Bad Ems, Germany), transcutaneous PCO2
(PtcCO2) (Tina TCM3
s, Radiometer, Kopenhagen,
Denmark), and ABG in the early morning were
measured at baseline without NPPV and at both
control visits with NPPV. Polysomnography was
performed according to the criteria of the Amer-
ican Thoracic Society15 and was scored according to
the criteria elaborated by Rechtschaffen and
Kales.16 In addition, measurements of ventilation
were performed during both control visits using a
pneumotachograph (Ventrak-Respiratory-Monitor-
ing-Systems Model 1550, Novametrix Medical
System Inc., Wallingford, USA) which was placed
between the mask and the expiratory valve.
Statistical analysis
Statistical analysis was performed using Sigma-Stat
(Version 2.03, SPSS Inc., Chicago, IL, USA). Data are
presented as mean 7 standard deviation (SD) after
testing for normal distribution. Statistical analysis
of data was performed using the paired t-test if
data were normally distributed or using the
Wilcoxon’s signed-ranks test if data were not
normally distributed. Correlation analysis was
performed using the Pearson product moment
correlation (rP). Statistical significance was as-
sumed with a P-value of o0.05.
Results
Ten patients completed the study protocol which
allowed a comparative analysis of the two modes of
ventilation. Five patients had COPD (mean age
66.675.8 years; three female, two male; mean
body mass index (BMI) 29.074.7 kg/m2; mean FEV1
0.8070.22 l; mean FVC 1.370.4 l), with a past
medical history of heavy smoking. Five male
patients had restrictive ventilatory disease (mean
age 47.0718.3 years; mean BMI 41.6716.0 kg/m2;
mean FEV1 1.6370.93 l; mean FVC 2.071.2 l) due
to obesity hypoventilation syndrome, achondropla-
sia, post-polio syndrome, post-tuberculosis seque-
lae, and amyotrophic lateral sclerosis. Two patients
with COPD were on long-term oxygen therapy
(LTOT) prior to NPPV (mean flow 2 l/min). Two
patients with restrictive ventilatory disease and
one patient with COPD additionally suffered from
obstructive sleep apnea.
Five patients had to be excluded from the study:
One patient with Duchenne muscular dystrophy was
successfully adapted on pl-NPPV and then switched
to vl-NPPV, but died due to cardiac arrest between
the first and second control visit. Two patients with
COPD were successfully adapted on pl-NPPV, but
refused to switch to vl-NPPV reporting intolerance
during vl-NPPV due to more bothersome gastro-
intestinal side effects. Both patients continued pl-
NPPV at home. The remaining two patients had
COPD and could not be adapted on any form of
NPPV and were discharged with LTOT.
There was neither any evidence of ARF nor of an
acute exacerbation due to a respiratory infection
during the whole study period in all patients. The
mean WBC at baseline was 850072000 (norm
4300–10000)/ml, mean CRP was 1.572.2 (norm
o0.5)mg/dl, mean haemoglobin was 15.271.1
(norm 12.0–18.0) g/dl, and mean haematocrit was
46.673.8 (norm 37.0–52.0)%, respectively. Minimal
pH breathing room air was 7.37 at baseline, 7.38 at
the control visit for vl-NPPV, and 7.37 at the control
visit for pl-NPPV. In addition, there was no clinical
evidence of hypothyroidism.
Pulmonary function parameters did not change
significantly following NPPV. Maximal inspiratory
mouth pressures (PImax) increased non-significantly
during vl-NPPV and pl-NPPV (Table 1). Breathing
room air PaCO2 and HCO3
 decreased significantly
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and PaO2 increased significantly following both
types of NPPV (Table 1). Mean haemoglobin
decreased from 15.271.1 to 14.471.3 g/dl in both
vl- and pl-NPPV (Po0:05). Accordingly, mean
haematocrit decreased from 46.673.8% (baseline)
to 43.074.0% in vl-NPPV (Po0:05) and to
43.973.8% in pl-NPPV (Po0:05), respectively.
WBC and CRP did not change significantly following
NPPV.
PaCO2, HCO3
, and PtcCO2 during nocturnal
vl- and pl-NPPV decreased significantly (Table 1).
Accordingly, PaO2 and SaO2 increased significantly,
and the heart rate decreased significantly (Table 1).
There was also an improvement in all domains of
sleep quality, but this was only significant for sleep
efficiency (vl-NPPV), and for arousals (pl-NPPV)
(Table 1). When vl- and pl-NPPV where directly
compared no clinically significant differences were
found for nocturnal ABG and sleep quality.
The daily use of the ventilator assessed by the
displayed working hours was 8.3 h/day during
vl-NPPV, and 7.8 h/day during pl-NPPV, respectively
(P¼ not significant). The ventilator settings and the
pneumotachographic measurements of the ventila-
tion parameters are given in Table 2. The expira-
tory volume (Vexp) was significantly lower compared
to the Vinsp both during vl and pl-NPPV (Po0:001)
indicating considerable leakage during both modes
of NPPV. The Vinsp was higher during pl-NPPV
despite a lower Pinsp compared to vl-NPPV, but this
was not statistically significant. Accordingly, the
leak volume (Vleak) calculated as the difference
between Vinsp and Vexp was non-significantly higher
during pl-NPPV. In addition, the Vleak during vl- and
pl-NPPV was well correlated (rP ¼ 0:88; Po0:001;
Fig. 1). There was a higher variance of Pinsp during
vl-NPPV compared to pl-NPPV as indicated by the
higher SD. In contrast, the Vinsp was more variable
during pl-NPPV. In addition, the measured Vinsp was
comparable to the inspiratory volume set in vl-
NPPV (Table 2). In contrast, the measured Pinsp was
significantly lower compared to the pressure set in
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Table 1 ABG, polysomnographic data, lung function parameters, and mouth occlusion pressures. Baseline data
and measurements after establishment of NPPV with supplemental oxygen (N ¼ 10).
Measurements during night
Baseline vl-NPPV P-valuen pl-NPPV P-valuen
PaCO2 (mmHg) 54.678.0 46.276.1 0.031 46.576.4 0.037
PaO2 (mmHg) 59.6710.9 85.2725.1 0.007 71.4717.5 0.052
pH 7.3970.06 7.4170.05 0.509 7.3970.03 0.954
HCO3
 (mmol/l) 32.474.5 28.572.9 0.005 28.373.1 0.008
PtcCO2 (mmHg) 60.7711.9 49.6710.1 0.025 49.576.0 0.016
Total sleep time (min) 1837100 243787 0.091 2107111 0.388
Slow wave sleep (%) 26.4717.2 31.9713.3 0.486 29.7715.3 0.593
REM sleep (%) 9.776.6 18.2712.9 0.375 16.379.1 0.099
Sleep efficiency (%) 44.2724.1 64.8722.3 0.033 52.5729.2 0.326
AHI (/h) 29.8734.3 9.579.8 0.096 7.378.8 0.070
Arousals (/h) 29.5728.1 12.478.5 0.120 8.474.5 0.004
Mean SaO2 (%) 86.178.5 94.971.8 0.011 93.172.8 0.033
Desaturations (/h) 34.7743.6 10.8714.3 0.124 16.0715.8 0.224
Heart rate (/h) 81.6715.1 67.6714.9 0.020 69.5713.3 0.014
Measurements during daytime
Baseline vl-NPPV P-valuen pl-NPPV P-valuen
P0.1 (kPa) 0.3370.15 0.3270.17 0.693 0.3170.12 0.561
PImax (kPa) 5.975.0 6.375.3 0.175 6.275.0 0.486
P0.1/PImax (%) 8.475.9 6.874.1 0.370 7.275.0 0.492
PaCO2 (mmHg) 47.776.1 43.274.7 0.015 43.475.0 0.069
PaO2 (mmHg) 55.979.7 62.978.6 0.030 60.879.3 0.093
PH 7.4170.03 7.4070.02 0.177 7.4070.02 0.324
HCO3
 (mmol/l) 29.873.5 26.672.34 0.003 26.673.2 0.023
AHI¼Apnea/hypopnea index, pl-NPPV¼Pressure-limited non-invasive positive pressure ventilation, PtcCO2¼ transcutaneous
PCO2, vl-NPPV¼Volume-limited non-invasive positive pressure ventilation.
Measurements during night were performed while on NPPV, and seven patients additionally received supplemental oxygen (1 or
2 l/min) while on NPPV during night. Measurements during daytime were performed while breathing room air at rest.
nCompared to baseline data.
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pl-NPPV (Table 2). NPPV was well tolerated, since
positive results, i.e. values of 0 to þ 2, were gained
in almost all items of the questionnaire concerning
tolerance of NPPV. However, gastrointestinal side
effects were more frequent in vl-NPPV compared to
pl-NPPV (Fig. 2).
Discussion
This is the first controlled cross-over study compar-
ing nocturnal nasal vl- and pl-NPPV in patients with
hypercapnic CRF. The main finding is that the
efficacy of nocturnal ventilation is comparable
between both modes of NPPV despite their techni-
cal differences. Accordingly, improvements in ABG
and sleep quality were comparable. In the past,
several uncontrolled studies have focused on
differences between vl- and pl-NPPV.7–10 In one
study VT significantly increased while fB as well as
the oesophageal pressure (as an index of inspiratory
muscle work) significantly both decreased during
vl- and pl-NPPV in patients who were well
acquainted with assisted ventilation, although MV
significantly decreased only during vl-NPPV.8 In
another study, two ventilators providing vl-NPPV
and two ventilators providing pl-NPPV were con-
sidered to be of comparable usefulness for home
mechanical ventilation.7 However, both studies
were only performed during wakefulness, and did
not include any further follow-up. At present, there
are two studies which compared vl- and pl-NPPV
with a long-term follow up.9,10 In the study by
Sch .onhofer et al. the majority of patients who had
been successfully ventilated by vl-NPPV were also
adequately ventilated when switched to pl-NPPV,
but a small subgroup of patients with more severe
disease deteriorated after being changed from vl-
NPPV to pl-NPPV.9 In contrast, the study by Smith
and Shneerson showed that pl-NPPV improved
symptoms and ABG in selected patients who had
been initially successfully adapted on vl-NPPV, but
who had deteriorated over a mean interval of about
2 years during vl-NPPV.10 However, both studies
were uncontrolled and did not include sleep
studies.
In our study, the overall efficacy of ventilation
was comparable between vl- and pl-NPPV. However,
there was a low variance of Vinsp, but more variable
Pinsp during vl-NPPV, and a low variance of Pinsp, but
more variable Vinsp during pl-NPPV. Although not
significant, there was a trend towards a higher Vleak
during pl-NPPV, but leak compensation was more
ARTICLE IN PRESS
Table 2 Ventilator settings and pneumotachographic measurements of the ventilation parameters during
nocturnal vl- and pl-NPPV (N ¼ 10).
Ventilator settings Pneumotachygraphic measurements
vl-NPPV pl-NPPV vl-NPPV pl-NPPV
Vinsp (ml) 6777133 F 7047151 7697264
Vexp (ml) F F 3057114 326793
Vleak (ml) F F 3997176 4437312
Pinsp (mbar) F 26.676.4
* 25.576.8 22.974.6*
I/E-ratio 0.5170.06 0.5470.10 0.5070.04 0.5770.07
fB (/min) 20.573.1 20.572.5 21.674.6 20.373.1
fB¼Breathing frequency, Vexp¼ Expiratory volume, Vinsp¼ Inspiratory volume, Vleak¼ Leak volume (calculated from the
difference of Vinsp and Vexp), pl-NPPV¼Pressure-limited non-invasive positive pressure ventilation, Pinsp¼Peak inspiratory
pressure, vl-NPPV¼Volume-limited non-invasive positive pressure ventilation. Po0:05 comparing ventilator settings and
pneumotachygraphic measurements.
In pl-NPPV (PV401s, Breas Medical AB, Moelnlycke, Sweden) the plateau was set at 8.2070.92.
Leak volume (Vleak) in vl-NPPV
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Figure 1 Pearson correlation analysis (rP) between Vleak
during vl- and pl-NPPV (N ¼ 10). pl-NPPV¼ pressure-
limited non-invasive positive pressure ventilation, vl-
NPPV¼ volume-limited non-invasive positive pressure
ventilation, Vleak¼ Leak volume (calculated from the
difference of Vinsp and Vexp).
56 W. Windisch et al.
evident during pl-NPPV compared to vl-NPPV.
Interestingly, our results support the findings of
two other laboratories in which leak-compensating
capabilities of different ventilators providing pl-
NPPV have been shown to be superior to different
ventilators providing vl-NPPV.4,17 However, leak
compensation during pl-NPPV was incomplete as
suggested by the observation that the Pinsp was
significantly lower than the pressure set. This is
supported by the finding that the decrease of Pinsp
is related to the severity of the leak,4 since the
leaks in our study were substantial with Vleak being
higher than 50% of Vinsp during both vl and pl-NPPV.
This is comparable to the results gained by Bach
and co-workers in which mild to severe air leakage
was evident during most of the time of night in
patients with kyphoscoliosis.18
In the present study sleep quality improved
following nocturnal ventilation, but did not normal-
ize. This might be explained by the substantial air
leakage which has been shown to compromise sleep
quality during nocturnal NPPV.18,19 In another
study, the reduction of oral air leaks by taping the
mouth led to a decrease in PtcCO2 and arousal
index, and to an increase in rapid eye movement
sleep.20 This highlights the clinical importance of
leak reduction during nocturnal NPPV. In contrast,
an impressive reduction of arousals following both
vl- and pl-NPPV despite the lack of leak prevention
in our study is consistent with findings by
Sch .onhofer and K.ohler,21 and different to findings
of Teschler et al. who reported comparable reduc-
tions in arousals only in patients who had their
mouth taped. This discrepancy could be due to
different ventilation techniques. BiPAP S/T used in
the study by Teschler et al. with lower IPAP and
higher EPAP might have caused mistriggering or
worsening of gas exchange,20 but this remains
speculative. Interestingly, leaks during vl- and pl-
NPPV in our study were highly correlated indicating
that air leakage during nocturnal NPPV more likely
depends on individual factors of the patient such as
specific oromotor activity18 and not on the differ-
ent ventilator modes used in our study. Full-face
masks were only used in 6%–9% of patients with
home mechanical ventilation in a recent European
survey including 19 000 patients from 16 different
countries.5 Nevertheless, the increase in VT and MV
and the decrease of PaCO2 were more significant in
patients with hypercapnic CRF who used a full-face
mask instead of a nasal mask in another study, but
the type of ventilator mode had less effects on the
efficacy of ventilation.22 From these data, it might
be speculated that the leak compensation of
ventilators is clinically less important than the
prevention of leaks.
There were more frequent gastrointestinal side
effects during vl-NPPV such as gastric distension
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and flatulence which is most likely due to higher
Pinsp during vl-NPPV compared to pl-NPPV. This
assumption is supported by the previous observa-
tion in a large cohort of 276 patients where 50%
suffered from gastric distension, belching, or
increased flatulence receiving vl-NPPV.23 In another
study, pl-NPPV was preferred to vl-NPPV by patients
who were established on nocturnal NPPV21 support-
ing the observation that pl-NPPV is individually
better tolerated than vl-NPPV.
The present study is the first prospective,
randomized, and cross-over design comparing
pl- and vl-NPPV in patients with hypercapnic CRF
of different etiologies. Some of its findings, how-
ever, might be due to the design and execution:
The choice of specific ventilators might have
affected the results of our study. Gas delivery
characteristics, particularly with regard to leak
compensation differ significantly between different
ventilators when compared in a laboratory set-
ting,4,17,24 whereas these differences seem to be of
lesser clinical relevance when tested in vivo.25
Vocal cord closure has been reported with con-
trolled ventilation,26,27 and this can affect airway
impedance, occurrence of leakage, and some of the
variability of Pinsp and Vinsp in our study. In addition,
although nocturnal vl and pl-NPPV have been shown
to improve gas exchange and sleep quality in
patients with hypercapnic CRF in a similar fashion
in this study, vl-NPPV might be more difficult during
initiation of NPPV. Furthermore, successful NPPV-
therapy depends on the expertise with the respec-
tive mode of NPPV at a particular centre.
In this exploratory study patients with CRF of
different etiologies and co-existing obstructive
sleep apnea were included in the study to compare
the two modes of ventilation in a broader range of
patients. Patients included in this analysis suffered
from moderate hypercapnic CRF, and we cannot
exclude that differences in the efficacy of ventila-
tion might become more apparent in patients with
a greater impedance to inflation. Furthermore, the
relatively small number of patients included in the
study may not have detected minor statistically
significant differences between the two treatment
groups. It seems questionable, however, that such a
potential differencesFif at all present in a larger
sample sizeFwould be clinically meaningful. Ob-
viously our results will have to be corroborated in
further studies with larger, more homogeneous
groups of patients with preferably more severe
hypercapnic CRF to address long-term results
including compliance in vl-NPPV versus pl-NPPV.
Patients in our study were consecutively en-
rolled. We thus eliminated pre-selection on the
basis of motivation or prognosis. This consecutive
enrolment, however, most likely also contributed
to the relatively high drop-out rate of 33%. Yet, the
number of patients who did not tolerate NPPV
during their inpatient stay was comparable to
previous investigations.28 Two COPD-patients were
successfully initiated on pl-NPPV, but later refused
to switch to vl-NPPV because of more gastrointest-
inal side effects while trying vl-NPPV. Similar side
effects were observed in those patients who
completed the study. Our two definite drop-outs
could not be adapted to any form of NPPV had also
COPD as the underlying illness, suggesting that
successful NPPV might be more difficult to initiate
and maintain in patients with COPD compared to
patients with restrictive ventilatory disorders.
We enrolled only patients with stable disease and
no signs or symptoms of an exacerbation. Never-
theless, vl- and pl-NPPV have been shown to
improve gas exchange during ARF29–31 with similar
results, although pl-NPPV was also better toler-
ated.29,31
In conclusion, vl-NPPV applied in patients with
CRF at night is associated with a low variance of
Vinsp, but more variable Pinsp while pl-NPPV is
associated with a low variance of Pinsp, but more
variable Vinsp. Substantial air leaks are present
during nocturnal NPPV when a nasal mask is used
irrespective of the mode of ventilatory support.
Although pl-NPPV resulted in insignificantly higher
leak volumes there was also better leak compensa-
tion. Despite these differences nocturnal vl- and pl-
NPPV improve gas exchange and sleep quality in
patients with hypercapnic CRF to a comparable
degree. Nocturnal vl-NPPV is, however, associated
with more gastrointestinal side effects.
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